Revlimid for Acute Meylogenous Leukemia – pro
Lenalidomide has clinical activity in AML with manageable toxicity. Unfortunately, its therapuetic profile has not been entirely worked out. The phenomena of the elderly, frail patient who cannot tolelrate standard therapies is an urgent clicnal problem in AML. .The population that would benefit from lenalidomide and optimal dose needs to be better defined. Recent trials have focused on combining lenalidomide with other agents active in MDS and AML and promising data are emerging. However, this remains an area of investigation, it is not possible to confidently predict how much it will help this patient, especially in combination, and there are no guidelines that recommend it.
Chen Y, Borthakur G. Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013 Mar;22(3):389-97.
William Blum, Rebecca B. Klisovic, Heiko Becker, Xiaoxia Yang, Darlene M. Rozewski, Mitch A. Phelps,
Ramiro Garzon, Alison Walker, Jason C. Chandler, Susan P. Whitman, John Curfman, Shujun Liu, Larry Schaaf, Jon Mickle, Cheryl Kefauver, Steven M. Devine, Michael R. Grever, Guido Marcucci, and John C. Byrd, Dose Escalation of Lenalidomide in Relapsed or Refractory
Acute Leukemias, JCO Oct. 18, 2010